Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
---|
11/02/2000 | EP1047437A1 Sea cucumber carotenoid lipid fraction products and methods of use |
11/02/2000 | EP1047436A2 Methods of treating tardive dyskinesia and other movement disorders |
11/02/2000 | EP1047428A1 Pharmaceutically active morpholinol |
11/02/2000 | EP1047427A1 Combination of a gaba-a alpha 2/3 agonist and a selective serotonin reuptake inhibitor |
11/02/2000 | EP1047416A2 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis |
11/02/2000 | EP1047415A1 Pig appeasing pheromones to decrease stress, anxiety and aggressiveness |
11/02/2000 | EP1047412A1 New use of local anaesthetics against vascular headaches |
11/02/2000 | EP1047409A1 Tts containing an antioxidant |
11/02/2000 | EP0914331B1 Neuroactive peptides |
11/02/2000 | EP0853619B1 Disubstituted piperidine derivatives |
11/02/2000 | EP0848592B1 Antistress agents for aquatic animals |
11/02/2000 | EP0808312B1 Indole derivatives as 5-ht receptor antagonist |
11/02/2000 | EP0790059A4 Means for treating auto-immune diseases and method of treatment |
11/02/2000 | DE19917990A1 Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk Medicines containing inhibitors of cell volume-regulated human kinase h-sgk |
11/02/2000 | CA2371274A1 Selective npy (y5) antagonists |
11/02/2000 | CA2371241A1 Tgf-.alpha. polypeptides, functional fragments and methods of use therefor |
11/02/2000 | CA2371064A1 Methods of delivery of cetyl myristoleate |
11/02/2000 | CA2371017A1 Cell therapy for chronic stroke |
11/02/2000 | CA2370241A1 Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression |
11/02/2000 | CA2370195A1 Human membrane-associated proteins |
11/02/2000 | CA2369999A1 Enzymatically activated polymeric drug conjugates |
11/02/2000 | CA2369942A1 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients |
11/02/2000 | CA2368213A1 Specifically targeted catalytic antagonists and uses thereof |
11/02/2000 | CA2367965A1 Human gil-19/ae289 proteins and polynucleotides encoding same |
11/02/2000 | CA2367695A1 Heteroaryl diazacycloalkanes, their preparation and use |
11/02/2000 | CA2367682A1 Tetracyclic azepinoindole compounds as 5-ht receptor ligands |
11/02/2000 | CA2367681A1 Azaindole derivatives for the treatment of depression |
11/01/2000 | CN1272139A Nucleic acids coding for proteins capable of interacting with presenilins |
11/01/2000 | CN1272108A Indole derivatives as 5-HT1B and 5-HT1D agonists |
11/01/2000 | CN1271734A Substituted 19-norsteroid, its preparation and intermediate and its medical use and composition |
11/01/2000 | CN1271731A New thiazole benzimidazole derivative |
11/01/2000 | CN1058013C Process for preparation of novel mercaptoacetylamide derivatives |
11/01/2000 | CN1058009C 8-oxy-5,8-dihydro-6H-dibenzo [a,g] quinolizine -13-propionic acid derivant, its preparation method and medicinal use thereof |
11/01/2000 | CN1058008C Phenyl heterocycles as cyclooxygenase-2 inhibitors |
11/01/2000 | CN1057929C Xueguiling analgesic |
10/31/2000 | US6140532 O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same |
10/31/2000 | US6140372 Acyl derivatives of melatonin and of melatoninergic analogues and their use as medicinal products |
10/31/2000 | US6140363 Administering rosmarinic acid, its derivative or prunella vulgaris extract for suppressing immune response for treatment, prevention, or diagnosis of rejection of transplanted organ or tissue, chronic rejection |
10/31/2000 | US6140357 Small molecule inhibitors of rotamase enzyme activity |
10/31/2000 | US6140354 N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
10/31/2000 | US6140352 Carbazolyl-substituted ethanolamines as selective β-3 agonists |
10/31/2000 | US6140345 For treating psychoses and pain |
10/31/2000 | US6140337 Methods for the treatment of mental disorders |
10/31/2000 | US6140336 Spiro[2H-1-benzopyran-2,4'-piperidine]-4(3H)-one derivatives, acid addition salts thereof and pharmaceutical compositions containing them |
10/31/2000 | US6140331 For treating anxiety disorders, depression, psychosis, impulse control disorders, alcohol abuse, ischaemic diseases, cardiovascular disorders, side effects induced by conventional antipsychotic agents and senile dementia |
10/31/2000 | US6140327 Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor |
10/31/2000 | US6140321 Polymorphs of donepezil hydrochloride and process for production |
10/31/2000 | US6140309 Inhibiting the vasoactive effects of beta-amyloid peptides by exposing vessel to a modifier of superoxide formation prior to exposure of the vessel to a amyloid peptide |
10/31/2000 | US6140116 Adjusted swine neuronal cells for the treatment of humans with stroke, brain trauma, amyotrophic lateral sclerosis, multiple sclerosis, huntington's and alzheimer's disease |
10/31/2000 | US6140112 Pharmaceutical compositions and their use, namely for the treatment of neurodegenerative diseases |
10/31/2000 | US6139877 Spheroids containing tiagabine, preparation process and pharmaceutical compositions |
10/31/2000 | CA2151724C Antipyretic and analgesic methods and compositions containing optically pure r-ketorolac |
10/31/2000 | CA1341131C Human nerve growth factor |
10/27/2000 | CA2307108A1 Process for production of mammalian cell lines, produced cell lines and their uses |
10/27/2000 | CA2307022A1 Agent for enhancing cerebral acetylcholine release |
10/27/2000 | CA2306574A1 Methods and compositions for treating age-related behavioral disorders in companion animals |
10/26/2000 | WO2000063702A1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
10/26/2000 | WO2000063441A2 Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease |
10/26/2000 | WO2000063415A1 Dna encoding the human vanilloid receptor vr1 |
10/26/2000 | WO2000063379A2 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof |
10/26/2000 | WO2000063374A1 Synthetic transmembrane components |
10/26/2000 | WO2000063372A1 Synthetic signalling molecules |
10/26/2000 | WO2000063370A2 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes |
10/26/2000 | WO2000063367A1 A novel family of beta sub-unit proteins from a voltage-gated sodium channel, nucleic acids encoding them and therapeutic or diagnostic uses thereof |
10/26/2000 | WO2000063246A2 Compounds and methods for modulating beta-catenin mediated gene expression |
10/26/2000 | WO2000063241A2 Methods and compositions for modulating an immune response |
10/26/2000 | WO2000063230A2 49 human secreted proteins |
10/26/2000 | WO2000063228A1 Ent-steroids as selectively active estrogens |
10/26/2000 | WO2000063215A2 Indazole derivatives, preparation and therapeutic application thereof |
10/26/2000 | WO2000063210A1 Morphinoid compounds |
10/26/2000 | WO2000063208A1 Substituted imidazoles, their preparation and use |
10/26/2000 | WO2000063204A2 Substituted azoles |
10/26/2000 | WO2000063203A1 Piperidine-indole compounds having 5-ht6 affinity |
10/26/2000 | WO2000063190A1 New compounds, their preparation and use |
10/26/2000 | WO2000063181A1 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins |
10/26/2000 | WO2000063179A1 Neurotrophin potentiators |
10/26/2000 | WO2000063169A2 N-dimethyl amino ethanol carboxylate pyrrolidone hydrate in its crystallised form |
10/26/2000 | WO2000063166A1 Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands |
10/26/2000 | WO2000063153A1 New compounds, their preparation and use |
10/26/2000 | WO2000062801A2 Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv) |
10/26/2000 | WO2000062800A2 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
10/26/2000 | WO2000062798A2 Angiogenic growth factors for treatment of peripheral neuropathy |
10/26/2000 | WO2000062797A1 Remedies for autonomic neuropathy |
10/26/2000 | WO2000062791A1 D-form polypeptide which induces immune tolerance and methods of use |
10/26/2000 | WO2000062786A2 Compositions containing rubidium and in particular rubidium chloride as an antimanic agent and stabilizer for mood swings |
10/26/2000 | WO2000062782A1 Novel synthesis and crystallization of piperazine ring-containing compounds |
10/26/2000 | WO2000062781A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
10/26/2000 | WO2000062780A1 Use of glucosylceramide synthesis inhibitors in therapy |
10/26/2000 | WO2000062779A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
10/26/2000 | WO2000062778A1 Cyclic protein tyrosine kinase inhibitors |
10/26/2000 | WO2000062773A1 Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects |
10/26/2000 | WO2000062770A1 Compounds useful as phosphotyrosine mimics |
10/26/2000 | WO2000062766A2 Uses of ppar-gamma agonists in neutrophil-induced diseases |
10/26/2000 | WO2000062765A2 ESTROGEN RECEPTOR-β LIGANDS |
10/26/2000 | WO2000062764A1 Gum pad for delivery of medication to mucosal tissues |
10/26/2000 | WO2000062757A1 Composition containing opioid antagonists and spray dispenser |
10/26/2000 | WO2000039120A3 Compounds and methods for modulation of estrogen receptors |
10/26/2000 | WO2000037064A3 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
10/26/2000 | WO2000035919A3 Quinoline derivatives |
10/26/2000 | WO2000032751A3 Mammalian non-neuronal cells that are modified to store and release a neurotransmitter |